EAM Investors LLC raised its stake in GlycoMimetics, Inc. (NASDAQ:GLYC) by 9.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 371,030 shares of the biotechnology company’s stock after buying an additional 32,285 shares during the quarter. GlycoMimetics comprises approximately 0.7% of EAM Investors LLC’s investment portfolio, making the stock its 24th biggest holding. EAM Investors LLC owned 1.13% of GlycoMimetics worth $5,191,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GLYC. Dynamic Technology Lab Private Ltd bought a new position in GlycoMimetics in the second quarter valued at approximately $146,000. Fox Run Management L.L.C. bought a new position in GlycoMimetics in the third quarter valued at approximately $173,000. Citadel Advisors LLC bought a new position in GlycoMimetics in the second quarter valued at approximately $249,000. Russell Investments Group Ltd. lifted its position in shares of GlycoMimetics by 172.4% in the second quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 19,859 shares in the last quarter. Finally, TD Asset Management Inc. bought a new stake in shares of GlycoMimetics in the second quarter worth $362,000. 88.32% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on GLYC. Zacks Investment Research raised shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Monday, November 13th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price objective on shares of GlycoMimetics in a research report on Thursday, October 26th. Roth Capital began coverage on shares of GlycoMimetics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price objective on the stock. SunTrust Banks, Inc. reissued a “buy” rating and issued a $21.00 price objective on shares of GlycoMimetics in a research report on Wednesday, October 4th. Finally, ValuEngine raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.33.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/20/eam-investors-llc-increases-holdings-in-glycomimetics-inc-glyc.html.

Shares of GlycoMimetics, Inc. (NASDAQ GLYC) traded up $0.09 on Monday, reaching $12.27. 177,400 shares of the company were exchanged, compared to its average volume of 945,486. GlycoMimetics, Inc. has a fifty-two week low of $3.82 and a fifty-two week high of $16.94.

GlycoMimetics (NASDAQ:GLYC) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. analysts anticipate that GlycoMimetics, Inc. will post -1.12 EPS for the current year.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $13.00, for a total value of $26,000.00. Following the transaction, the senior vice president now directly owns 150,615 shares in the company, valued at $1,957,995. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 43.80% of the stock is owned by insiders.

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Stock Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related stocks with our FREE daily email newsletter.